Labcorp (NYSE:LH) Given New $350.00 Price Target at Truist Financial

Labcorp (NYSE:LH) had its target price lifted by Truist Financial from $320.00 to $350.00 in a research note released on Friday,Benzinga reports. They currently have a buy rating on the medical research company’s stock.

Several other research firms have also recently issued reports on LH. Evercore reaffirmed an “outperform” rating and issued a $300.00 price target on shares of Labcorp in a report on Wednesday, April 8th. Wall Street Zen raised Labcorp from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Bank of America lifted their target price on Labcorp from $300.00 to $320.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Barclays boosted their target price on Labcorp from $290.00 to $320.00 and gave the stock an “equal weight” rating in a research report on Thursday. Finally, Robert W. Baird upped their target price on Labcorp from $335.00 to $338.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $323.27.

Labcorp Stock Performance

NYSE:LH opened at $309.47 on Friday. The company has a 50-day moving average of $274.71 and a 200-day moving average of $271.01. The firm has a market cap of $25.38 billion, a price-to-earnings ratio of 25.60, a price-to-earnings-growth ratio of 2.09 and a beta of 0.89. The company has a current ratio of 1.80, a quick ratio of 1.54 and a debt-to-equity ratio of 0.69. Labcorp has a twelve month low of $244.52 and a twelve month high of $316.11.

Labcorp (NYSE:LH) last released its earnings results on Thursday, July 30th. The medical research company reported $4.99 EPS for the quarter, topping analysts’ consensus estimates of $4.78 by $0.21. The business had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.71 billion. Labcorp had a net margin of 6.99% and a return on equity of 16.74%. The business’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the previous year, the firm earned $4.35 EPS. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. Analysts forecast that Labcorp will post 18.04 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 28th will be issued a dividend of $0.72 per share. The ex-dividend date is Friday, August 28th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.9%. Labcorp’s payout ratio is currently 25.51%.

Insider Activity at Labcorp

In related news, EVP Kathryn W. Kyle sold 92 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total value of $26,329.48. Following the completion of the transaction, the executive vice president owned 3,904 shares of the company’s stock, valued at approximately $1,117,285.76. This trade represents a 2.30% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Bryan T. Vaughn sold 234 shares of Labcorp stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $286.19, for a total transaction of $66,968.46. Following the transaction, the executive vice president owned 6,746 shares in the company, valued at approximately $1,930,637.74. The trade was a 3.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 6,991 shares of company stock worth $1,796,696. 0.84% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of LH. Thurston Springer Miller Herd & Titak Inc. acquired a new position in Labcorp during the fourth quarter valued at $26,000. Hilton Head Capital Partners LLC acquired a new position in shares of Labcorp in the 4th quarter valued at about $27,000. JPL Wealth Management LLC purchased a new stake in shares of Labcorp in the third quarter worth approximately $28,000. Eagle Bay Advisors LLC acquired a new stake in shares of Labcorp during the fourth quarter worth approximately $29,000. Finally, DV Equities LLC acquired a new stake in shares of Labcorp during the fourth quarter worth approximately $29,000. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Labcorp News Roundup

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Labcorp exceeded expectations in the second quarter, reporting adjusted EPS of $4.99 versus the $4.78 analyst consensus and revenue of $3.73 billion versus estimates of $3.71 billion. Revenue increased 5.8% year over year, supported by steady diagnostic-testing demand and growth in drug-development services. Reuters article
• Positive Sentiment: The company raised its 2026 adjusted EPS guidance to $18.10-$18.55, above the roughly $17.99-$18.00 consensus, while forecasting revenue of approximately $14.71 billion-$14.83 billion. Diagnostics Laboratories revenue rose 5.5%, and Biopharma Laboratory Services revenue increased 6.5%. Labcorp second-quarter results
• Positive Sentiment: Labcorp expanded its share-repurchase authorization by $1 billion, repurchased $353.8 million of stock during the quarter and paid $58.7 million in dividends. Truist Financial also raised its price target from $320 to $350 and assigned a “buy” rating, implying further upside from recent levels. Benzinga reference
• Neutral Sentiment: Management highlighted continued investment in oncology, consumer health and technology initiatives. The earnings call transcripts provide additional detail on demand trends, margins and the updated outlook. Labcorp Q2 earnings call transcript
• Negative Sentiment: Despite the earnings and revenue beats, LH shares fell in premarket trading and remain lower in active trading. The reaction indicates that investors may have viewed the results and raised outlook as insufficient relative to elevated expectations and the stock’s recent rally toward its 52-week high. Zacks market reaction
• Negative Sentiment: Recent insider-trading data shows company insiders made multiple sales and no purchases over the past six months, a potential sentiment headwind, although the transactions do not necessarily reflect management’s outlook. Quiver Quantitative report

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.